Sooma Medical Revolutionizes Depression Treatment with €5M Funding Boost
March 13, 2024, 1:20 pm
Location: Finland, Southern Finland Province, Helsinki
Employees: 11-50
Founded date: 2013
Total raised: $6.85M
Sooma Medical, a healthtech company based in Helsinki, Finland, has secured a €5 million funding boost to expand its innovative Transcranial Direct Current Stimulation (tDCS) at-home depression treatment. This new funding brings Sooma's total funding to €7.5 million, allowing the company to accelerate product development and expand into new markets, including the US.
tDCS is a non-invasive therapy that uses a mild electrical current to stimulate the brain and alleviate depression symptoms without the need for pharmaceuticals. Sooma's portable neuromodulation device offers a safe and effective way to manage depression symptoms at home, providing relief without the side effects commonly associated with antidepressant medications.
Sooma's tDCS therapy has been proven effective in placebo-controlled trials, with the majority of patients experiencing symptom relief within a few weeks. This treatment has helped patients overcome severe work impairment and return to their regular routines, offering a powerful alternative to traditional depression treatments.
The company's dedication to reaching underserved populations and providing access to high-quality care for those suffering from depression sets Sooma apart in the mental health tech industry. By offering a prescription-only therapy that can be safely administered at home, Sooma is changing the way we approach depression treatment on a global scale.
With the support of investors like Voima Ventures and Verge HealthTech Fund, Sooma is poised to continue its mission of revolutionizing depression treatment and improving the lives of those battling this debilitating condition. The company's commitment to innovation and patient-centered care is paving the way for a brighter future for individuals struggling with depression worldwide.
tDCS is a non-invasive therapy that uses a mild electrical current to stimulate the brain and alleviate depression symptoms without the need for pharmaceuticals. Sooma's portable neuromodulation device offers a safe and effective way to manage depression symptoms at home, providing relief without the side effects commonly associated with antidepressant medications.
Sooma's tDCS therapy has been proven effective in placebo-controlled trials, with the majority of patients experiencing symptom relief within a few weeks. This treatment has helped patients overcome severe work impairment and return to their regular routines, offering a powerful alternative to traditional depression treatments.
The company's dedication to reaching underserved populations and providing access to high-quality care for those suffering from depression sets Sooma apart in the mental health tech industry. By offering a prescription-only therapy that can be safely administered at home, Sooma is changing the way we approach depression treatment on a global scale.
With the support of investors like Voima Ventures and Verge HealthTech Fund, Sooma is poised to continue its mission of revolutionizing depression treatment and improving the lives of those battling this debilitating condition. The company's commitment to innovation and patient-centered care is paving the way for a brighter future for individuals struggling with depression worldwide.